Optimal Treatment for Patients with Oligometastatic Prostate Cancer

ÇETİN B., Wabl C. A., Gumusay O.

UROLOGIA INTERNATIONALIS, vol.106, no.3, pp.217-226, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 106 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.1159/000519386
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, Gender Studies Database, MEDLINE
  • Page Numbers: pp.217-226
  • Keywords: Oligometastatic disease, Prostate cancer, Local treatment, Systemic therapy, BIOCHEMICAL RECURRENCE, RADICAL PROSTATECTOMY, BODY RADIOTHERAPY, SURVIVAL, THERAPY, METASTASES, MEN, C-11-CHOLINE, DISEASE, BURDEN
  • Süleyman Demirel University Affiliated: Yes


Oligometastatic prostate cancer (PCa) can be defined as cancer with a limited number of metastases, typically fewer than 5 lesions, and involves lesions contained within the axial versus the appendicular skeleton. Patients can present with de novo oligometastatic, oligorecurrent, or oligoprogressive PCa. Oligometastatic PCa patients demonstrate considerable improvements in survival outcomes, with a better prognosis than patients with extensive metastatic disease. However, the management of patients that present with nonsymptomatic oligometastatic PCa remains difficult. In the oligometastatic setting, the benefit of local therapies such as prostatectomy and radiotherapy on survival outcomes is an intriguing topic; however, their impact on oncological outcomes is still unknown.